CL2007003793A1 - Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a l - Google Patents
Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a lInfo
- Publication number
- CL2007003793A1 CL2007003793A1 CL200703793A CL2007003793A CL2007003793A1 CL 2007003793 A1 CL2007003793 A1 CL 2007003793A1 CL 200703793 A CL200703793 A CL 200703793A CL 2007003793 A CL2007003793 A CL 2007003793A CL 2007003793 A1 CL2007003793 A1 CL 2007003793A1
- Authority
- CL
- Chile
- Prior art keywords
- union
- antagonists
- amiloid
- molecula
- app
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87152806P | 2006-12-22 | 2006-12-22 | |
US90084807P | 2007-02-12 | 2007-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003793A1 true CL2007003793A1 (es) | 2008-07-25 |
Family
ID=39535220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200703793A CL2007003793A1 (es) | 2006-12-22 | 2007-12-21 | Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a l |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100203044A1 (es) |
EP (1) | EP2094732A2 (es) |
JP (1) | JP2010514700A (es) |
KR (1) | KR20090094854A (es) |
AR (1) | AR064501A1 (es) |
AU (1) | AU2007336770A1 (es) |
BR (1) | BRPI0719459A2 (es) |
CA (1) | CA2671903A1 (es) |
CL (1) | CL2007003793A1 (es) |
CO (1) | CO6210755A2 (es) |
MX (1) | MX2009006685A (es) |
NO (1) | NO20092741L (es) |
NZ (1) | NZ577436A (es) |
PE (1) | PE20081546A1 (es) |
RU (1) | RU2009128039A (es) |
SG (1) | SG177924A1 (es) |
TW (1) | TW200844113A (es) |
WO (1) | WO2008080045A2 (es) |
ZA (1) | ZA201004219B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011005481A (es) * | 2008-11-25 | 2011-08-17 | Biogen Idec Inc | Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso. |
TW201034684A (en) * | 2009-02-18 | 2010-10-01 | Genentech Inc | Method for inhibiting neurodegeneration |
CA2780319A1 (en) * | 2009-11-12 | 2011-05-19 | Genentech, Inc. | A method of promoting dendritic spine density |
JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US20120238465A1 (en) * | 2011-03-17 | 2012-09-20 | Joseph Audie | Drug screening target for alzheimer's disease and method of screening potential drugs |
CN102708565A (zh) * | 2012-05-07 | 2012-10-03 | 深圳市贝尔信智能系统有限公司 | 一种前景检测的方法、装置和系统 |
EP3058371B1 (en) * | 2013-10-14 | 2021-06-16 | Indiana University Research and Technology Corporation | Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
WO2015076282A1 (ja) | 2013-11-20 | 2015-05-28 | 国立大学法人北海道大学 | 免疫制御剤 |
US20170174734A1 (en) * | 2014-03-12 | 2017-06-22 | Temple University-Of The Commonwealth System Of Higher Education | DR6 Receptor Mediates the Leukemia Differentiation Activity of Angiocidin: A Potent Anti-Tumor Peptide |
IL274285B (en) | 2015-03-16 | 2022-07-01 | Regeneron Pharma | Non-human animals exhibiting reduced upper and lower motor neuron function and sensory perception |
CN106794222B (zh) * | 2015-03-26 | 2021-08-24 | 苏州澳宗生物科技有限公司 | 使用p75ecd和/或p75诊断或治疗神经障碍的方法 |
WO2017193096A1 (en) * | 2016-05-06 | 2017-11-09 | Abbvie Stemcentrx Llc | Novel anti-tnfrsf21 antibodies and methods of use |
KR102351126B1 (ko) * | 2019-12-03 | 2022-01-13 | 재단법인대구경북과학기술원 | App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3702789A1 (de) * | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
DK0939121T4 (da) * | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
WO1991016628A1 (en) * | 1990-04-24 | 1991-10-31 | The Regents Of The University Of California | Purification, detection and methods of use of protease nexin-2 |
US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
JP3277211B2 (ja) * | 1991-11-12 | 2002-04-22 | プラナ・バイオテクノロジー・リミテッド | アルツハイマー病の試験方法と治療方法 |
CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US6013476A (en) * | 1997-04-02 | 2000-01-11 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor TR7 |
US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
US6949358B1 (en) | 1997-06-11 | 2005-09-27 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor TR9 |
US7378507B2 (en) * | 1997-09-18 | 2008-05-27 | Genentech, Inc. | PRO217 polypeptides |
US6194151B1 (en) * | 1997-09-26 | 2001-02-27 | Millenium Pharmaceuticals, Inc. | Molecules of the TNF receptor superfamily and uses therefor |
FR2778858B1 (fr) * | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
US6916907B1 (en) * | 1998-10-23 | 2005-07-12 | Curagen Corporation | Nucleic acids encoding osteoprotegern-like proteins and methods of using same |
US6423494B1 (en) * | 1999-03-25 | 2002-07-23 | Millennium Pharmaceuticals, Inc. | DR6 and uses thereof |
AT5874U1 (de) * | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
AU2002255881A1 (en) * | 2001-03-23 | 2002-10-08 | University Of Utah Research Foundation | Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use |
CN100488982C (zh) * | 2001-11-02 | 2009-05-20 | 迪尔基因国际有限公司 | 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法 |
US20050208050A1 (en) * | 2001-11-09 | 2005-09-22 | Gerd Multhaup | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
EP1455825A4 (en) * | 2001-12-17 | 2006-05-31 | Lilly Co Eli | TREATMENT OF B-CELL-MEDIATED DISEASES BY MODULATION OF THE DR6 ACTIVITY |
EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
ES2301280A1 (es) * | 2005-05-16 | 2008-06-16 | Fina Biotech S.L.U. | Metodo para diagnosticar la enfermedad de alzheimer. |
US20100099609A1 (en) * | 2008-07-28 | 2010-04-22 | Buck Institute For Age Research | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE |
CA2780319A1 (en) * | 2009-11-12 | 2011-05-19 | Genentech, Inc. | A method of promoting dendritic spine density |
-
2007
- 2007-12-21 MX MX2009006685A patent/MX2009006685A/es not_active Application Discontinuation
- 2007-12-21 RU RU2009128039/10A patent/RU2009128039A/ru not_active Application Discontinuation
- 2007-12-21 TW TW096149573A patent/TW200844113A/zh unknown
- 2007-12-21 CA CA002671903A patent/CA2671903A1/en not_active Abandoned
- 2007-12-21 AU AU2007336770A patent/AU2007336770A1/en not_active Abandoned
- 2007-12-21 NZ NZ577436A patent/NZ577436A/en not_active IP Right Cessation
- 2007-12-21 JP JP2009543252A patent/JP2010514700A/ja active Pending
- 2007-12-21 SG SG2011096492A patent/SG177924A1/en unknown
- 2007-12-21 AR ARP070105866A patent/AR064501A1/es not_active Application Discontinuation
- 2007-12-21 EP EP07869737A patent/EP2094732A2/en not_active Withdrawn
- 2007-12-21 KR KR1020097015353A patent/KR20090094854A/ko not_active Application Discontinuation
- 2007-12-21 BR BRPI0719459-5A2A patent/BRPI0719459A2/pt not_active IP Right Cessation
- 2007-12-21 WO PCT/US2007/088521 patent/WO2008080045A2/en active Application Filing
- 2007-12-21 CL CL200703793A patent/CL2007003793A1/es unknown
- 2007-12-21 US US12/520,044 patent/US20100203044A1/en not_active Abandoned
-
2008
- 2008-01-02 PE PE2008000033A patent/PE20081546A1/es not_active Application Discontinuation
-
2009
- 2009-07-16 CO CO09074363A patent/CO6210755A2/es not_active Application Discontinuation
- 2009-07-21 NO NO20092741A patent/NO20092741L/no not_active Application Discontinuation
-
2010
- 2010-06-14 ZA ZA2010/04219A patent/ZA201004219B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR064501A1 (es) | 2009-04-08 |
WO2008080045A2 (en) | 2008-07-03 |
JP2010514700A (ja) | 2010-05-06 |
US20100203044A1 (en) | 2010-08-12 |
TW200844113A (en) | 2008-11-16 |
SG177924A1 (en) | 2012-02-28 |
MX2009006685A (es) | 2009-07-27 |
NZ577436A (en) | 2012-05-25 |
PE20081546A1 (es) | 2008-12-22 |
RU2009128039A (ru) | 2011-01-27 |
ZA201004219B (en) | 2013-02-27 |
CA2671903A1 (en) | 2008-07-03 |
BRPI0719459A2 (pt) | 2014-02-04 |
KR20090094854A (ko) | 2009-09-08 |
AU2007336770A1 (en) | 2008-07-03 |
CO6210755A2 (es) | 2010-10-20 |
EP2094732A2 (en) | 2009-09-02 |
WO2008080045A3 (en) | 2008-09-12 |
NO20092741L (no) | 2009-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003793A1 (es) | Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a l | |
SV2011003834A (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
NI200900081U (es) | Anticuerpos agonistas de trkb y sus usos. | |
CY2016005I1 (el) | Αλκαλικη φωσφαταση στοχευμενη στα οστα, κιτ και μεθοδοι χρησης αυτων | |
CO6450665A2 (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
BRPI0819412A2 (pt) | dispositivos de teste de hidratação | |
DK2036990T3 (da) | Diagnostisk test for følsomheden over for B-Raf-kinaseinhibitorer | |
CL2014000400A1 (es) | Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11). | |
DE602008004964D1 (de) | Vorrichtung zur Messung der Fluoreszenzlebenszeit | |
BRPI0811612A2 (pt) | Composições farmacêuticas que contêm agonista ppardelta | |
BRPI0820447A2 (pt) | Agonistas do receptor de glicocorticóides | |
DK2049478T3 (da) | Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf | |
CL2007003784A1 (es) | Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato | |
CL2007001011A1 (es) | Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip. | |
DK2027096T3 (da) | Substituerede arylimidazoloner og -triazoloner som inhibitorer for vasopressinreceptorerne | |
BRPI0813580A2 (pt) | Antagonistas de receptor 1 de hormônio de concentração de melanina não básicos e métodos | |
BRPI0813457A2 (pt) | Composto de organoenxofre contendo halogênio e uso do mesmo | |
CO6362052A2 (es) | Antagonistas de los receptores tipo toll 3. | |
DE602006002289D1 (de) | Vorrichtung zur Messung der Körperzusammensetzung | |
AR060440A1 (es) | Agonistas receptores de eritropoietina | |
FI20075363A (fi) | Kompassilaite ja menetelmä kompassilaitetta varten | |
FI20075191A0 (fi) | Väline ja menetelmä analyysiä varten | |
BRPI0822915A2 (pt) | Clínquer de cimento inorgânico, sua preparação e cimento inorgânico que compreende o clínquer | |
CL2007003613A1 (es) | Compuestos nitroderivados, antagonistas del receptor de angiotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension. | |
PE20080908A1 (es) | Agonistas lxr para el tratamiento de osteoartritis |